Researchers conducted a retrospective analysis of 1435 patients with limited cutaneous SSc from the Italian SPRING registry to assess the purpose of starting mycophenolate mofetil treatment and its ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted a prior approval supplement to Zydus Lifesciences Limited allowing the company to market its ...

Please provide your email address to receive an email when new articles are posted on . Tacrolimus alone had a dose-response relationship with achieving complete renal response in SLE. Combination ...

In a new analysis of the BLISS LN trial, researchers added Belimumab (Benlysta) to Mycophenolate (MMF), the standard of care treatment for lupus nephritis, (LN, lupus-related kidney disease) and found ...

† One patient had MMF as an initial treatment. ‡ In the study TAC and MMF were used alone or in combination. §In total, 17 patients were initially treated with MMF and steroids. ¶ Females represented ...

ATLANTA — New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, demonstrated that withholding mycophenolate mofetil for at least 10 days ...

Credit: Azurity Pharmaceuticals. Myhibbin is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection. Myhibbin is expected to be commercially available in the second ...

LONDON, Dec 14 (Reuters) - The European Medicines Agency has recommended approval of Teva Pharmaceutical Industries Ltd's generic versions of the organ rejection drug CellCept, the watchdog said on ...

CellCept (mycophenolate mofetil) is a prescription drug that’s used to help prevent organ rejection after an organ transplant. The most common side effects reported with CellCept include diarrhea and ...

The influence of psychosocial factors on first-time chemotherapy-induced nausea and vomiting: A prospective multicenter cohort study.